美国Sequel治疗制剂公司是加利福尼亚州Cytel公司与Scripps研究所的合资公司,目前已就CY1899向美国食品与药物管理局(FDA)提出实验性新药(IND)申请。CY1899是一种慢性乙型肝炎治疗疫苗,如果FDA批准,则马上进行临床试验。这种疫苗是将乙型肝炎疫苗片段插到巨噬细胞上主要组织相容性复合物(MHC)中以刺激细胞毒性T细胞应答。细胞毒性T细胞是免疫系统中唯一能杀伤慢性感染 Sequel Therapeutics, a joint venture between Cytel and the Scripps Research Institute in California, has filed an application for an experimental new drug (IND) with the US Food and Drug Administration (FDA) for CY1899. CY1899 is a chronic hepatitis B vaccine that will undergo immediate clinical trials if approved by the FDA. This vaccine inserts a hepatitis B vaccine fragment into the major histocompatibility complex (MHC) on macrophages to stimulate a cytotoxic T-cell response. Cytotoxic T cells are the only ones in the immune system that can kill chronic infections